Trial Information
Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaMuscle, Bone, and Cartilage DiseasesEnrollment279% Female17%% White98%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0168T51Data PartnerJohnson & JohnsonCondition StudiedSpondylitis, Ankylosing (Nonradiographic Axial)Mean/Median Age (Years)40
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0732 : Assessment of peripheral arthritis and related disease activity measurement instruments in spondyloarthritis
- 2022-5080 : Validating a Personalised Ankylosing Spondylitis Metrology Index.
- 2022-4962 : SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials
- 2019-3893 : Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis
- 2018-2761 : Relationship between decreased bone mineral density and syndesmophyte development: a multilevel analysis in patients with Ankylosing Spondylitis
- 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials